All posts by: Michael Zand

About Michael Zand

Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2% – Seeking Alpha

Continue reading

2017-07-18 NEWS

Thorold News

Maxim bullish on Abeona, sees 89% upside on prospects of lead gene therapy candidate EB-101; shares up 2%
Seeking Alpha
Maxim Group ups its fair value target for Abeona Therapeutics (ABEO +2.2%) to $17 (89% upside) from $14 citing positive prospects for its lead gene therapy candidate, Orphan Drug-tagged EB-101, for the treatment of recessive dystrophic epidermolysis …
Maxim Group Just Issued “Buy” Rating on Abeona Therapeutics Inc (ABEO)Highland Mirror
Analysts are on the Bearish side about Abeona Therapeutics Inc (NASDAQ:ABEO) this week.WeeklyHub

all 50 news articles »

Continue reading

2017-07-18 NEWS

Oppenheimer Starts Coverage on Editas Medicine, Inc. (EDIT) By Announcing An Initial Rating Of “Perform”
Highlight Press
CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular …

and more »

Continue reading

2017-07-18 NEWS

Oppenheimer Starts Coverage on Editas Medicine, Inc. (EDIT) By Announcing An Initial Rating Of “Perform”
Highlight Press
CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular …

and more »

Continue reading

2017-07-18 NEWS

New Gene Therapy Routes for Motor Disease Uncovered in New Study
Drug Discovery & Development
Scientists investigating the genetic causes and altered functioning of nerve cells in motor neurone disease (MND) have discovered a new mechanism that could lead to fresh treatment approaches for one of the most common forms of the disease. The team …

Continue reading

2017-07-18 NEWS

NormanObserver.com

Oppenheimer Starts Coverage on Editas Medicine, Inc. (EDIT) By Announcing An Initial Rating Of “Perform”
Highlight Press
CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular …
Oppenheimer Begins Coverage on Editas Medicine, Inc. (EDIT) With …First News 24

all 11 news articles »